Avaliação do possível efeito terapêutico de um mimético da interleucina-10 no modelo de fibromialgia em camundongos

Abstract

Fibromyalgia is the second most common rheumatic syndrome, with a prevalence of 2-3 % worldwide. It is characterized by choronic widespread pain, associated with other comorbidities such as anxiety and depression. The treatment for fibromyalgia consists of the use of different pharmacological and non pharmacological therapies the treatment available does not resolve the disease, and they have several undesirable adverse effects. There is evidence of an imbalance in the production of cytokines, such IL-10, in fibromyalgia. Thus, we aimed to investigate the effects of IL10 in pain, anxious and depression in a model of fibromyalgia. Male C57BL6 mice were used in this study (CEUA 030/19). The fibromyalgia-like pain model was induced by a subcutaneous administration of reserpine (0,25mg/Kg) or saline (10 mL/Kg) for three consecutive days. After the last administration of reserpine, the animals were treated intranasally, with 20 µL of 40 µg/uL vehicle (PBS) or doses of 10 µg/µL, 30 µg/µL and 100 µg/µL of the IL-10 mimetic. On the last 4 day after the administration of reserpine and 4 h after the treatment with the IL-10 mimetic, parameters of pain, anxious and depressive behavior evaluated observed. Reserpine causes mechanical hypersensitivity in response to Von Frey filaments, anxiety-like and depressive-like behavior, and reduced muscle strength. Treatment with mimetic IL-10 at doses of 30 µg/µL and 100 µg/µL inhibited mechanical allodynia. And it improved depressive and anxious parameters, and muscle performance. The present study demonstrates the antinociceptive and neuroprotective potential of the IL-10 mimetic in reserpine-induced fibromyalgia model. However, more studies are necessary to understand the mechanisms involved in these effects.